Alessandro Raffaele1, Fabrizio Vatta2, Martina Votto3, Amelia Licari3,4, Maria Ruffoli2, Marco Brunero2, Gianluigi Marseglia3,4, Giovanna Riccipetitoni2,4. 1. Pediatric Surgery Unit, Department of Maternal and Child Health, Fondazione IRCCS-Policlinico San Matteo, Pavia, Italy. a.raffaele@smatteo.pv.it. 2. Pediatric Surgery Unit, Department of Maternal and Child Health, Fondazione IRCCS-Policlinico San Matteo, Pavia, Italy. 3. Pediatrics Unit, Department of Maternal and Child Health, Fondazione IRCCS-Policlinico San Matteo, Pavia, Italy. 4. Department of Clinical-Surgical, Diagnostic and Pediatric Science, University of Pavia, Pavia, Italy.
Abstract
PURPOSE: Eosinophilic gastrointestinal disorders are rare in children and present with a broad spectrum of non-specific symptoms. To date, no guidelines for diagnosis, therapy and follow-up are validated. Aim of our study is to focus on eosinophilic colitis (EC), to determine a possible correlation between associated disorders, macroscopic findings and treatment/follow up. METHODS: Retrospective study from 2015 to 2019 including all colonoscopies performed at our Institution. Eosinophilic colitis was defined according to the threshold identified by Collins: > 100 Eo/Hpf: right colon, > 84 Eo/Hpf transverse and left colon, > 64 Eo/Hpf sigma and rectum. We excluded colonoscopy in patients with IBD or other diseases causing hypereosinophilia (i.e., parasite infection, GVHD). RESULTS: Among 399 colonoscopies performed in 355 patients, we made 50 diagnosis of EC, 36 males, 14 females, median age 8.5 (3-17). Symptoms leading to endoscopy were recurrent abdominal pain (66%), chronic diarrhea (64%), and chronic constipation (8%). Two patients presented with GI bleeding and one with weight loss. Macroscopic findings were mostly normal or lymphoid nodular hypertrophy presenting different endoscopic features. In seven children (14%) we found history of allergy and atopy. 22 children present a diagnosis of autistic spectrum disorder (ASD) with a prevalence higher than in the overall population (44% vs 28.5%, p = 0.03). According to symptoms, treatment consist variably of steroids, six food elimination diet, mesalamine. For patients with available follow-up, we found histological persistence of Eosinophils in 75%, even in patients with symptoms relief. CONCLUSION: This study focus attention on EC as a new challenging pathology. Multicentric randomized clinical trials are needed to understand physiopathological mechanisms to validate a possible endoscopic score and related histological threshold, and to standardize therapy according to clinical features and instrumental findings. The high prevalence of EC in ASD need further specific research.
PURPOSE:Eosinophilic gastrointestinal disorders are rare in children and present with a broad spectrum of non-specific symptoms. To date, no guidelines for diagnosis, therapy and follow-up are validated. Aim of our study is to focus on eosinophilic colitis (EC), to determine a possible correlation between associated disorders, macroscopic findings and treatment/follow up. METHODS: Retrospective study from 2015 to 2019 including all colonoscopies performed at our Institution. Eosinophilic colitis was defined according to the threshold identified by Collins: > 100 Eo/Hpf: right colon, > 84 Eo/Hpf transverse and left colon, > 64 Eo/Hpf sigma and rectum. We excluded colonoscopy in patients with IBD or other diseases causing hypereosinophilia (i.e., parasite infection, GVHD). RESULTS: Among 399 colonoscopies performed in 355 patients, we made 50 diagnosis of EC, 36 males, 14 females, median age 8.5 (3-17). Symptoms leading to endoscopy were recurrent abdominal pain (66%), chronic diarrhea (64%), and chronic constipation (8%). Two patients presented with GI bleeding and one with weight loss. Macroscopic findings were mostly normal or lymphoid nodular hypertrophy presenting different endoscopic features. In seven children (14%) we found history of allergy and atopy. 22 children present a diagnosis of autistic spectrum disorder (ASD) with a prevalence higher than in the overall population (44% vs 28.5%, p = 0.03). According to symptoms, treatment consist variably of steroids, six food elimination diet, mesalamine. For patients with available follow-up, we found histological persistence of Eosinophils in 75%, even in patients with symptoms relief. CONCLUSION: This study focus attention on EC as a new challenging pathology. Multicentric randomized clinical trials are needed to understand physiopathological mechanisms to validate a possible endoscopic score and related histological threshold, and to standardize therapy according to clinical features and instrumental findings. The high prevalence of EC in ASD need further specific research.
Authors: Theresa A Heifert; Apryl Susi; Elizabeth Hisle-Gorman; Christine R Erdie-Lalena; Gregory Gorman; Steve B Min; Cade M Nylund Journal: J Pediatr Gastroenterol Nutr Date: 2016-10 Impact factor: 2.839
Authors: Peter Capucilli; Antonella Cianferoni; Robert W Grundmeier; Jonathan M Spergel Journal: Ann Allergy Asthma Immunol Date: 2018-09-06 Impact factor: 6.347
Authors: Elizabeth T Jensen; Christopher F Martin; Michael D Kappelman; Evan S Dellon Journal: J Pediatr Gastroenterol Nutr Date: 2016-01 Impact factor: 2.839
Authors: Robert D Pesek; Craig C Reed; Amanda B Muir; Patricia C Fulkerson; Calies Menard-Katcher; Gary W Falk; Jonathan Kuhl; Ellen K Martin; Adam Z Magier; Faria Ahmed; Maureen Demarshall; Ankur Gupta; Jonathan Gross; Tokunbo Ashorobi; Christina L Carpenter; Jeffrey P Krischer; Nirmala Gonsalves; Jonathan M Spergel; Sandeep K Gupta; Glenn T Furuta; Marc E Rothenberg; Evan S Dellon Journal: Am J Gastroenterol Date: 2019-06 Impact factor: 10.864
Authors: Carlo Maria Rossi; Marco Vincenzo Lenti; Stefania Merli; Amelia Licari; Martina Votto; Gian Luigi Marseglia; Antonio Di Sabatino Journal: Clin Transl Allergy Date: 2022-05-23 Impact factor: 5.657
Authors: Marc E Rothenberg; Shawna K B Hottinger; Nirmala Gonsalves; Glenn T Furuta; Margaret H Collins; Nicholas J Talley; Kathryn Peterson; Calies Menard-Katcher; Macie Smith; Ikuo Hirano; Robert M Genta; Mirna Chehade; Sandeep K Gupta; Jonathan M Spergel; Seema S Aceves; Evan S Dellon Journal: J Allergy Clin Immunol Date: 2021-12-22 Impact factor: 10.793